David Reboussin to Genetic Testing
This is a "connection" page, showing publications David Reboussin has written about Genetic Testing.
Connection Strength
0.212
-
Adams P, Barton JC, McLaren GD, Acton RT, Speechley M, McLaren CE, Reboussin DM, Leiendecker-Foster C, Harris EL, Snively BM, Vogt T, Sholinsky P, Thomson E, Dawkins FW, Gordeuk VR, Eckfeldt JH. Screening for iron overload: lessons from the hemochromatosis and iron overload screening (HEIRS) study. Can J Gastroenterol. 2009 Nov; 23(11):769-72.
Score: 0.083
-
McLaren GD, McLaren CE, Adams PC, Barton JC, Reboussin DM, Gordeuk VR, Acton RT, Harris EL, Speechley MR, Sholinsky P, Dawkins FW, Snively BM, Vogt TM, Eckfeldt JH. Clinical manifestations of hemochromatosis in HFE C282Y homozygotes identified by screening. Can J Gastroenterol. 2008 Nov; 22(11):923-30.
Score: 0.078
-
Speechley M, Barton JC, Passmore L, Harrison H, Reboussin DM, Harris EL, Rivers CA, Fadojutimi-Akinsiku M, Wenzel L, Diaz S. Potential nonresponse bias in a clinical examination after initial screening using iron phenotyping and HFE genotyping in the hemochromatosis and iron overload screening study. Genet Test Mol Biomarkers. 2009 Dec; 13(6):721-8.
Score: 0.021
-
Barton JC, Acton RT, Leiendecker-Foster C, Lovato L, Adams PC, McLaren GD, Eckfeldt JH, McLaren CE, Reboussin DM, Gordeuk VR, Speechley MR, Reiss JA, Press RD, Dawkins FW. HFE C282Y homozygotes aged 25-29 years at HEIRS Study initial screening. Genet Test. 2007; 11(3):269-75.
Score: 0.017
-
Herrington DM, Vittinghoff E, Howard TD, Major DA, Owen J, Reboussin DM, Bowden D, Bittner V, Simon JA, Grady D, Hulley SB. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterioscler Thromb Vasc Biol. 2002 Jun 01; 22(6):1012-7.
Score: 0.012